Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Industry, Sector and Symbol
Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorComputer and Technology
CIKN/A
Phone888-280-2221
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.78 billion
Profitability
Miscellaneous
Employees5,000
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable
Covetrus (NASDAQ:CVET) Frequently Asked Questions
What is Covetrus' stock symbol?
Covetrus trades on the NASDAQ under the ticker symbol "CVET."
How were Covetrus' earnings last quarter?
Covetrus Inc (NASDAQ:CVET) posted its earnings results on Tuesday, November, 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.09. The firm earned $1.02 billion during the quarter, compared to analysts' expectations of $963.69 million. Covetrus had a negative net margin of 23.15% and a positive return on equity of 4.26%. Covetrus's quarterly revenue was up 10.3% on a year-over-year basis. View Covetrus' Earnings History.
When is Covetrus' next earnings date?
What price target have analysts set for CVET?
7 analysts have issued 12-month price objectives for Covetrus' shares. Their forecasts range from $11.00 to $21.00. On average, they expect Covetrus' stock price to reach $15.25 in the next year. This suggests a possible upside of 17.8% from the stock's current price. View Analyst Price Targets for Covetrus.
What is the consensus analysts' recommendation for Covetrus?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Covetrus.
Has Covetrus been receiving favorable news coverage?
Media stories about CVET stock have been trending extremely negative on Thursday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Covetrus earned a news sentiment score of -4.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Covetrus.
Who are some of Covetrus' key competitors?
What other stocks do shareholders of Covetrus own?
Who are Covetrus' key executives?
Covetrus' management team includes the folowing people:
- Benjamin J. Shaw, President, Chief Executive Officer & Director
- Christine Tomlinson Komola, Chief Financial Officer & Executive Vice President
- Matthew Leonard, Executive VP & President-North America
- Jim Young, Chief Human Resources Officer & Senior VP
- Erin Powers Brennan, Secretary, Senior Vice President & General Counsel
Who are Covetrus' major shareholders?
Covetrus' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.79%), State Street Corp (2.41%), First Trust Advisors LP (2.36%), Kovitz Investment Group Partners LLC (2.11%), Bank of New York Mellon Corp (0.96%) and FMR LLC (0.94%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Erin Powers Brennan and Timothy Ludlow. View Institutional Ownership Trends for Covetrus.
Which major investors are selling Covetrus stock?
CVET stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bank of America Corp DE, Credit Suisse AG, American International Group Inc., Gabelli Funds LLC, Man Group plc, Kovitz Investment Group Partners LLC and State Street Corp. Company insiders that have sold Covetrus company stock in the last year include Betsy S Atkins, David Christopher Dollar and Timothy Ludlow. View Insider Buying and Selling for Covetrus.
Which major investors are buying Covetrus stock?
CVET stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Prudential Financial Inc., Principal Financial Group Inc., BNP PARIBAS ASSET MANAGEMENT Holding S.A., Palisade Capital Management LLC NJ, Russell Investments Group Ltd., Public Sector Pension Investment Board and Madison Asset Management LLC. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw and Erin Powers Brennan. View Insider Buying and Selling for Covetrus.
How do I buy shares of Covetrus?
Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Covetrus' stock price today?
One share of CVET stock can currently be purchased for approximately $12.95.
How big of a company is Covetrus?
What is Covetrus' official website?
How can I contact Covetrus?
Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]
MarketBeat Community Rating for Covetrus (NASDAQ CVET)
MarketBeat's community ratings are surveys of what our community members think about Covetrus and other stocks. Vote "Outperform" if you believe CVET will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVET will underperform the S&P 500 over the long term. You may vote once every thirty days.
